Transvenous Approach for the Treatment of Cerebral Arteriovenous Malformations (TATAM)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03691870 |
|
Recruitment Status :
Recruiting
First Posted : October 2, 2018
Last Update Posted : August 10, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
A new endovascular route for the treatment of brain AVMs may be possible in some cases: Trans-Venous Embolization (TVE). The technique uses microcatheters to navigate to the draining veins of AVM, to reach and then fill the AVM nidus retrogradely with liquid embolic agents until the lesion is occluded. This technique has the potential to improve on some of the problems with the arterial approach to AVM embolization, such as a low overall occlusion rate. However, by occluding the vein first, and filling the lesion with the embolic agent in a retrograde fashion, the method transgresses a widely held dogma in the surgical or endovascular treatment of AVMs: to preserve the draining vein until all afferent vessels have been occluded. Nevertheless, the initial case series have shown promising results, with high occlusion rates, and few technical complications.
The method is increasingly used in an increasing number of centers, but there is currently no research protocol to guide the use of this promising but still experimental treatment in a prudent fashion. Care trials can be designed to offer such an experimental treatment, taking into account the best medical interests of patients, in the presence of rapidly evolving indications and techniques.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Arteriovenous Malformations, Cerebral Unruptured Brain Arteriovenous Malformation Ruptured Brain Arteriovenous Malformation | Procedure: Standard Trans-Arterial Embolization (TAE) Procedure: Trans-Venous Embolization (TVE) | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 76 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Transvenous Approach for the Treatment of Cerebral Arteriovenous Malformations (TATAM): A Randomized Controlled Trial and Registry |
| Actual Study Start Date : | August 2, 2018 |
| Estimated Primary Completion Date : | May 2023 |
| Estimated Study Completion Date : | December 2023 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: standard Trans-Arterial Embolization (TAE)
The standard TAE, without TVE, is used in patient allocated standard treatment. The arterial approach will consist of at least one attempted catheterization for trans-arterial injection of liquid embolic. Patients incompletely treated at the time of the final embolization procedure are adjudicated a failure to reach the primary outcome and can be treated using alternative standard options (including surgery, radiation therapy, conservative management). In addition, patients of the control group can also be offered TVE, if still feasible, once the TAE has been adjudicated to be a failure. If the operator deems, on the table, for a trans-arterial injection to be too dangerous, no arterial injection is necessary. Treatment, where indicated, can be completed through other means. |
Procedure: Standard Trans-Arterial Embolization (TAE)
The standard TAE, without TVE, is used in patient allocated standard treatment. The arterial approach will consist of at least one attempted catheterization for trans-arterial injection of liquid embolic. If the operator deems, on the table, for a trans-arterial injection to be too dangerous, no arterial injection is necessary. Treatment, where indicated, can be completed through other means. |
|
Experimental: Trans-Venous Embolization (TVE) (+/- Arterial) strategy
The experimental treatment is an attempt to completely occlude the AVM using venous catheterization and retrograde EVOH injection during the final session. TAE can be performed to prepare for final TVE during the same or one previous preparatory session, or TAE can be used to rescue an incomplete TVE. In some patients, balloon catheterization is used trans-arterially to assist TVE. It will be permissible to perform more than one treatment session when deemed necessary (occasionally to treat an AVM through the trans-venous route requires a two-stage approach, with a single trans-arterial attempt to decrease AVM filling prior to the definitive trans-venous approach, and this will be permitted). The trans-venous strategy will consist of at least one transvenous injection of ethyl vinyl alcohol (EVOH), with the choice of delivery microcatheters and other technical details left to the individual operator's discretion). |
Procedure: Trans-Venous Embolization (TVE)
The experimental treatment is an attempt to completely occlude the AVM using venous catheterization and retrograde EVOH injection during the final session. The trans-venous strategy will consist of at least one transvenous injection of ethyl vinyl alcohol (EVOH), with the choice of delivery microcatheters and other technical details left to the individual operator's discretion. |
- Angiographic evidence of residual AVM at time of confirmatory catheter angiography. [ Time Frame: 3 months +/- 1 month following embolization ]Angiographic evidence of residual AVM at time of confirmatory catheter angiography
- Failure to safely and effectively position the embolization microcatheter. [ Time Frame: within day of procedure ]Failure to reach a safe and effective microcatheter position for embolization.
- Any procedural complication leading to transient new neurological deficit. [ Time Frame: <5 days ]Any procedural complication leading to transient new neurological deficit.
- Any procedural complication leading to new neurological deficit. [ Time Frame: ≥5 days ]Any procedural complication leading to new neurological deficit.
- Any treatment-related complication that prolongs hospitalization by ≥5 days. [ Time Frame: Within one week ]Any treatment-related complication that prolongs hospitalization by ≥5 days.
- Incidence of new ischemia following treatment (Brain MR imaging prior to discharge with diffusion sequences). [ Time Frame: within 5 days post procedure ]Incidence of new ischemia following treatment (Brain MR imaging prior to discharge with diffusion sequences).
- Length of hospitalization (days). [ Time Frame: ≥5 days ]Length of hospitalization (days).
- Patient discharge to a location that is not his/her home. [ Time Frame: through to 3 (+/- 1) months follow-up ]Discharge to location other than home.
- mRS at discharge and 3(+/-1) months. [ Time Frame: through to 3 (+/- 1) months follow-up ]mRS at discharge and 3(+/-1) months.
- Incidence of new admission to hospital during follow-up. [ Time Frame: Within 3 +/- months post final treatment ]Incidence of new admission to hospital during follow-up.
- Incidence of intracranial hemorrhage during follow-up. [ Time Frame: Within 3 +/- months post final treatment ]Incidence of intracranial hemorrhage during follow-up.
- Incidence of residual AVM on confirmatory catheter angiography at 3(+/-1) months post-treatment. [ Time Frame: at 3(+/-1) months post-treatment. ]Incidence of residual AVM on confirmatory catheter angiography at 3(+/-1) months post-treatment.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | Child, Adult, Older Adult |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Any patient harboring a brain AVM (ruptured or unruptured) in whom TVE is considered a promising but yet unproven therapeutic option by the participating clinicians can be submitted to the Case Selection Committee.
- Patients must be in stable, non-urgent clinical condition, with the acute phase of the AVM rupture resolved (where applicable).
- Case must be approved by the CSC.
Notes on potentially suitable cases:
- Current indications may include (but are NOT restricted to) brain AVMs with a small <3 cm nidus (or small residual nidus), with a single draining vein, and for which curative treatment can be attained with one or at most two treatment sessions.
- Physicians are not required to submit cases prior to any or all treatment; a case can be submitted to the CSC for consideration after previous treatments (including previous arterial embolization sessions) have been performed. The timing of the submission of the case will be left to individual operators. Previously treated AVMs (by any other modality: embolization/surgical resection/radiosurgery) are not excluded from TATAM.
Exclusion Criteria:
- Absolute contra-indication to endovascular treatment or anesthesia.
- Inability to obtain informed consent.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03691870
| Contact: Jean Raymond, MD | 514-890-8000 ext 27235 | jraymond.nri@gmail.com | |
| Contact: Tim Darsaut, MD | 780-407-1440 | tdarsaut@ualberta.ca |
| Canada, Alberta | |
| University of Alberta Hospital | Recruiting |
| Edmonton, Alberta, Canada | |
| Contact: Tim Darsaut, MD tdarsaut@ualberta.ca | |
| Principal Investigator: Tim Darsaut, MD | |
| Canada, Quebec | |
| Centre Hospitalier de l'Université de Montréal | Recruiting |
| Montréal, Quebec, Canada, H2X 0C1 | |
| Contact: Guylaine Gevry 514-890-8000 ext 27235 guylaine.gevry.chum@ssss.gouv.qc.ca | |
| Contact: Ruby Klink, PhD 514-890-8000 ext 26359 Ruby.Klink@crchum.qc.ca | |
| Principal Investigator: Jean Raymond, MD | |
| Sub-Investigator: Daniel Roy, MD | |
| Sub-Investigator: Alain Weill, MD | |
| France | |
| Centre hospitalier universitaire de Bordeaux | Active, not recruiting |
| Bordeaux, France | |
| Centre hospitalier régional universitaire de Brest | Recruiting |
| Brest, France | |
| Contact: Jean-Christophe Gentric, MD jean-christophe.gentric@chu-brest.fr | |
| Principal Investigator: Jean-Christophe Gentric, MD | |
| Centre hospitalier universitaire de Grenoble | Recruiting |
| Grenoble, France | |
| Contact: Kamel Boubagra, MD KBoubagra@chu-grenoble.fr | |
| Principal Investigator: Kamel Boubagra, MD | |
| Sub-Investigator: Olivier Heck, MD | |
| Centre hospitalier universitaire Limoges | Recruiting |
| Limoges, France | |
| Contact: Emanuelle Lorian emmanuelle.lorian@chu-limoges.fr | |
| Principal Investigator: Charbel Mounayer, MD | |
| Hôpital Forndation Adolphe de Rothschild | Recruiting |
| Paris, France | |
| Contact: Michel Piotin, MD mpiotin@for.paris | |
| Principal Investigator: Michel Piotin, MD | |
| Centre hospitalier universitaire de Rouen Normandie | Recruiting |
| Rouen, France | |
| Contact: Chrysanthi Papagiannaki, MD C.Papagiannaki@chu-rouen.fr | |
| Principal Investigator: Chrysanthi Papagiannaki, MD | |
| Centre hospitalier universitaire de la Réunion | Recruiting |
| Saint-Paul, France | |
| Contact: Marc Bintner, MD 02 62 35 90 86 marc.bintner@chu-reunion.fr | |
| Principal Investigator: Marc Bintner, MD | |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Centre hospitalier de l'Université de Montréal (CHUM) |
| ClinicalTrials.gov Identifier: | NCT03691870 |
| Other Study ID Numbers: |
18.118 |
| First Posted: | October 2, 2018 Key Record Dates |
| Last Update Posted: | August 10, 2022 |
| Last Verified: | August 2022 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
brain arteriovenous malformation Arteriovenous malformations AVM BAVM stroke intracranial hemorrhage |
congenital abnormalities aneurysm vascular malformations cardiovascular abnormalities cardiovascular diseases vascular diseases |
|
Hemangioma Intracranial Arteriovenous Malformations Arteriovenous Malformations Congenital Abnormalities Vascular Malformations Cardiovascular Abnormalities Cardiovascular Diseases Vascular Diseases Neoplasms, Vascular Tissue |
Neoplasms by Histologic Type Neoplasms Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Central Nervous System Vascular Malformations Nervous System Malformations Intracranial Arterial Diseases |